title: Re: Propranolol treatment for hemangioma of infancy: risks and recommendations.
authors.forename: Susan J
authors.initials: SJ
authors.lastname: Bayliss
authors.forename: David R
authors.initials: DR
authors.lastname: Berk
authors.forename: George F
authors.initials: GF
authors.lastname: Van Hare
authors.forename: David
authors.initials: D
authors.lastname: Balzer
authors.forename: Kelvin
authors.initials: K
authors.lastname: Yamada
authors.forename: Gregg
authors.initials: G
authors.lastname: Lueder
authors.forename: Agustina
authors.initials: A
authors.lastname: Lanoel
authors.forename: Victoria
authors.initials: V
authors.lastname: de la Fuente
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Cordisco
mesh_terms: D001919:Bradycardia / Q000139:chemically induced; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007223:Infant; D007231:Infant, Newborn; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use; D012307:Risk Factors; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D011433:Propranolol